donepezil has been researched along with Ischemic Stroke in 2 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Ischemic Stroke: Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Donepezil has proven to be an effective drug to reduce neuronal death and subsequently injury in neurodegenerative diseases." | 5.62 | Donepezil attenuates injury following ischaemic stroke by stimulation of neurogenesis, angiogenesis, and inhibition of inflammation and apoptosis. ( Aboutaleb, N; Golmohammadi, S; Madani Neishaboori, A; Nasseri Maleki, S; Nazarinia, D; Saberi Pirouz, M, 2021) |
| "Donepezil has proven to be an effective drug to reduce neuronal death and subsequently injury in neurodegenerative diseases." | 1.62 | Donepezil attenuates injury following ischaemic stroke by stimulation of neurogenesis, angiogenesis, and inhibition of inflammation and apoptosis. ( Aboutaleb, N; Golmohammadi, S; Madani Neishaboori, A; Nasseri Maleki, S; Nazarinia, D; Saberi Pirouz, M, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barfejani, AH | 1 |
| Jafarvand, M | 1 |
| Seyedsaadat, SM | 1 |
| Rasekhi, RT | 1 |
| Madani Neishaboori, A | 1 |
| Nasseri Maleki, S | 1 |
| Saberi Pirouz, M | 1 |
| Golmohammadi, S | 1 |
| Nazarinia, D | 1 |
| Aboutaleb, N | 1 |
1 review available for donepezil and Ischemic Stroke
| Article | Year |
|---|---|
Donepezil in the treatment of ischemic stroke: Review and future perspective.
Topics: Animals; Cholinesterase Inhibitors; Donepezil; Humans; Ischemic Stroke; Neuroprotective Agents; Reco | 2020 |
1 other study available for donepezil and Ischemic Stroke
| Article | Year |
|---|---|
Donepezil attenuates injury following ischaemic stroke by stimulation of neurogenesis, angiogenesis, and inhibition of inflammation and apoptosis.
Topics: Angiogenesis Inducing Agents; Animals; Apoptosis; Donepezil; Dose-Response Relationship, Drug; Infar | 2021 |